Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
| Episode | Date |
|---|---|
|
How Can Europe Move from Innovation Paradox to Powerhouse, Cuno Moser?
|
May 01, 2026 |
|
Are primary research platforms adapting to payer dynamics, Shrutya Bhalla?
|
Apr 15, 2026 |
|
How Can Political Leadership Turn Health into an Economic Priority, Hatice Küçük Benton?
|
Apr 01, 2026 |
|
Is Europe Still More Attractive Than the US, China, India or MENA for Medtech Investment, Bernard Bichsel?
|
Mar 15, 2026 |
|
From Necessary Tasks to New Insights: How Can AI Act as a Sparring Partner in Market Access, Helmut Butscher?
|
Mar 01, 2026 |
|
Can Innovative Contracting Turn High‑Cost Therapies into Sustainable Deals, Omar Ali?
|
Feb 15, 2026 |
|
What Makes Australia’s HTA Approach to Equity and Health Productivity Unique, Zanfina Ademi?
|
Feb 01, 2026 |
|
No Decisions for Us, Without Us: Why Patient Advocacy Matters in Market Access, Erica Bersin?
|
Jan 15, 2026 |
|
Can VR and AR Finally Break Through the Barriers in Medical Innovation, Günther Illert?
|
Dec 15, 2025 |
|
Why Should Pharma and MedTech Innovators Look at New Zealand, Julius Ohrnberger?
|
Dec 01, 2025 |
|
Are We Ready for a Cultural Shift Toward AI in Pharma, Elizabeth Shanahan?
|
Nov 15, 2025 |
|
What Can Europe and the U.S. Learn from Each Other on Market Access, Anne Loos?
|
Nov 01, 2025 |
|
Will AI and Living Reviews Define the Next Era of Health Policy, Anna Forsythe?
|
Oct 15, 2025 |
|
Are We Undervaluing the Economic Power of Health, Dr. Malina Müller?
|
Oct 01, 2025 |
|
How Should Pharma Respond to the New Reality of Market Access in Germany, Prof. Dr. Thomas Hammerschmidt?
|
Sep 15, 2025 |
|
Do Swiss Reimbursement Reforms Open Doors—or Raise New Barriers, Petra Erni?
|
Sep 01, 2025 |
|
The Startup Guide to Navigating Healthcare Reimbursement, Featuring Ron de Graaff (Repost)
|
Aug 15, 2025 |
|
Europe vs. US: Who Leads the Future of Market Access, Dr. Doug Niven?
|
Aug 01, 2025 |
|
What Does It Really Take to Master AMNOG in Today’s Market Access Landscape, Anja Pownell?
|
Jul 15, 2025 |
|
Is Cross-Functional Alignment the Secret to Successful Market Access, Kasem Akhras?
|
Jul 01, 2025 |
|
How Do You Unlock the Power of Statistics in Market Access, Necdet Gunsoy?
|
Jun 15, 2025 |
|
How will AI shape the future of Market Access and Systematic Reviews, Jeffrey Johnson and Kevin Kallmes? (Repost)
|
Jun 01, 2025 |
|
How Can Market Access Professionals Plan for Long-Term Success, Adrian Kielhorn?
|
May 15, 2025 |
|
What Are the Biggest Challenges & Opportunities of JCA, Dr. Nick Leach?
|
May 01, 2025 |
|
Are We Overlooking the Real Benefits of Medical Innovation, Dr. Ahmed Seddik?
|
Apr 15, 2025 |
|
What Are the Biggest Challenges in Implementing AI in Pharma, Jan Kroschinski?
|
Apr 01, 2025 |
|
How Can Startups Leverage Market Access to Attract Investors, Johan Olsson?
|
Mar 15, 2025 |
|
How Are Data Privacy Laws Delaying Patient Access to New Treatments, Douglas Drake and Adam Skali?
|
Mar 01, 2025 |
|
How Can Innovation Planning Transform Market Access Success, Dr. Kasia Hein-Peters?
|
Feb 15, 2025 |
|
How does early Market Access bridge the gap between innovation and commercial success, Catherine Bacon?
|
Feb 01, 2025 |
|
A Flourishing Career in Pharmaceutical Market Access: Which Skills Are Essential, Dipti Tankala? (Repost)
|
Jan 15, 2025 |
|
What happens, when negotiations fail, Prof. Dr. Jürgen Wasem? (Repost)
|
Dec 15, 2024 |
|
How can people get equal access to pharmaceuticals, Dr. Nina Lathia? (Repost)
|
Dec 01, 2024 |
|
How might digitization change health care in Germany by 2035, Julian Molitor? (Repost)
|
Nov 15, 2024 |
|
How to optimize commercialisation of innovative life science products, Dr. Kasia Hein-Peters? (Repost)
|
Nov 01, 2024 |
|
What does environmental sustainability mean for Market Access, Gerdi Strydom?
|
Oct 15, 2024 |
|
What are the main obstacles in oncology market access, Ed Schoonveld? (Repost)
|
Oct 01, 2024 |
|
Is there a place for Real World Evidence in HTA, Dr. Karen Facey? (Repost)
|
Sep 15, 2024 |
|
How should market access and medical affairs work together, Dr. Mike Rosenblatt? (Repost)
|
Sep 01, 2024 |
|
Summer Special - Webinar: How AI can revolutionize dossier writing, with special guest Aleksey Zavgorodniy
|
Aug 15, 2024 |
|
What are the latest trends in Turkish Healthcare Market Access, Oznur Seyhun?
|
Aug 01, 2024 |
|
How will AI shape the future of Market Access and Systematic Reviews, Jeffrey Johnson and Kevin Kallmes?
|
Jul 15, 2024 |
|
How can Virtual Reality become a game-changer in Healthcare Training, Rodrigo Silva?
|
Jul 01, 2024 |
|
How Can AI Unlock the Potential of Market Access, Sandip Shah?
|
Jun 15, 2024 |
|
What Does the Future Hold for AI in Healthcare, Aleksey Zavgorodniy?
|
Jun 01, 2024 |
|
How to Decode Market Access in Canada: Are There Essential Tips for Success, Tara Cowling and Jody Filkowski?
|
May 15, 2024 |
|
How has virtual become reality in market access, Glib Kutepov?
|
May 01, 2024 |
|
What Makes Italy's Healthcare System So Complex, Giacomo Matteo Bruno?
|
Apr 16, 2024 |
|
Is Healthcare Just a Business in the US, Aymeric Chaupin?
|
Apr 01, 2024 |
|
A Flourishing Career in Pharmaceutical Market Access: Which Skills Are Essential, Dipti Tankala?
|
Mar 15, 2024 |
|
Mastering US Market Access: What are proven Strategies for Success, Paul-Lukas Hoffschmidt?
|
Mar 01, 2024 |
|
Beyond the CE Mark: How can we achieve Medtech Reimbursement in France, Dr. Benoit Salaun?
|
Feb 15, 2024 |
|
Remo Christen – Early paid access in Switzerland – Switzerland, wonderland? (Repost)
|
Feb 01, 2024 |
|
How can we overcome the complexity of market access for medical devices in Spain, Sergio Gil?
|
Jan 15, 2024 |
|
What is the secret of the cost-efficient healthcare system in Israel, Mirel Stelian? (Repost)
|
Dec 15, 2023 |
|
The Startup Guide to Navigating Healthcare Reimbursement, Featuring Ron de Graaff
|
Dec 01, 2023 |
|
Navigating the Healthcare Startup Galaxy - key insights with Dr. Thomas Kerscher and Mark Anken.
|
Nov 15, 2023 |
|
How to navigate complexities, Aurelie Moser: Market Access in Digital Health vs. Drugs?
|
Nov 01, 2023 |
|
AMNOG 2.0 - significant changes for the industry since January 2023, correct - Dr. Flume?
|
Oct 15, 2023 |
|
Inside the Swiss decision-makers - how does the system for drugs really work, Dr. Heiner Sandmeier?
|
Oct 01, 2023 |
|
How should market access and medical affairs work together, Dr. Mike Rosenblatt?
|
Sep 15, 2023 |
|
📠 How will Switzerland make the leap from FAX machines to Digital Healthcare, Dr. Peter Indra?
|
Sep 01, 2023 |
|
How does an optimized communication strategy look like, Dr. Arne Näveke?
|
Aug 15, 2023 |
|
How does the German evaluation committee work, Prof. Jürgen Wasem?
|
Aug 01, 2023 |
|
How to optimize commercialisation of innovative life science products, Dr. Kasia Hein-Peters?
|
Jul 15, 2023 |
|
How do I get approved by the US FDA, Dr. Jamie Cross?
|
Jul 01, 2023 |
|
How will the US Inflation Reduction Act change pricing of pharmaceuticals, Anita Burrell?
|
Jun 15, 2023 |
|
How does market access work in Japan, Heather Wellam?
|
Jun 01, 2023 |
|
Would AI substitute or (only) support market access managers, Dr. Andree Bates? (Repost)
|
May 15, 2023 |
|
Is there a place for Real World Evidence in HTA, Dr. Karen Facey?
|
May 01, 2023 |
|
How can people get equal access to pharmaceuticals, Dr. Nina Lathia?
|
Apr 15, 2023 |
|
How to be successful in Canadian health care market access & pricing!
|
Apr 01, 2023 |
|
How can companies prepare for EU Joint HTA, Priyanka Kiritharan and Chloe Sheppard?
|
Mar 15, 2023 |
|
Is quality cancer care in Ukraine still possible, Yevgen Brovko?
|
Mar 01, 2023 |
|
What are drivers for a positive approval by Health Canada, Fraidianie Sévignè?
|
Feb 15, 2023 |
|
EU joint HTA – decided, but how will it be executed and how should companies prepare, Dr. Elvira Müller?
|
Feb 01, 2023 |
|
The US pricing reform has an impact on Europe as well, correct Dr. Renato Dellamano and Jack Mycka?!
|
Jan 15, 2023 |
|
What are the main obstacles in oncology market access, Ed Schoonveld?
|
Jan 01, 2023 |
|
Why should companies get early advice from payers, Esther Nzenza and Dr. Nick Leach?
|
Dec 15, 2022 |
|
The AMNOG process - how does it work from a legal perspective, Alexander Meier?
|
Dec 01, 2022 |
|
What are the hot topics in market access based on ISPOR Europe 2022, Dr. Stefan Walzer?
|
Nov 15, 2022 |
|
AMNOG Reform - will Germany remain the most attractive market for orphan drugs?
|
Nov 01, 2022 |
|
Why should Market Access Managers care about statistics, Alexander Schacht?
|
Oct 15, 2022 |
|
How might digitization change health care in Germany by 2035, Julian Molitor?
|
Oct 01, 2022 |
|
Are selective contracts with German insurances a smarter reimbursement pathway, Tim Hering?
|
Sep 15, 2022 |
|
Would AI substitute or (only) support market access managers, Dr. Andree Bates?
|
Sep 01, 2022 |
|
How successful is the DiGA fast track, Dr. Henrik Matthies ?
|
Aug 15, 2022 |
|
The UK market access has always been complex, now even more than before, Graham Foxon and Paul Craddy?
|
Aug 01, 2022 |
|
Switzerland is strong in many aspects, so also in its health care system, Dr. Peter Indra?
|
Jul 15, 2022 |
|
AMNOG was the end of paradise for pharmaceutical companies, correct Prof. Hammerschmidt?
|
Jul 01, 2022 |
|
What is the secret of the cost-efficient healthcare system in Israel, Mirel Stelian?
|
Jun 15, 2022 |
|
Dutch payers are pragmatic, especially when discussing medical devices, isn’t it, Ron de Graaff?
|
Jun 01, 2022 |
|
The Belgium reimbursement pathway for digital health applications is similarly easy as in Germany, correct Katrien de Groote?
|
May 15, 2022 |
|
Is European market access really so difficult? Tell us the truth being successful in Europe, Esther Nzenza!
|
May 01, 2022 |
|
What can Europeans learn from Canada for the upcoming EU joint HTA, Gabriel Tremblay?
|
Apr 15, 2022 |
|
Digital Health Care is already fully utilized in the US, isn’t it?
|
Apr 01, 2022 |
|
Does the Italian reimbursement pathway allow for innovative drugs being highly priced, Dr. Stefano Capri and Dr. Entela Xoxi?
|
Mar 15, 2022 |
|
What are the specific elements about the Austrian market access pathway, Dr. Anna Bucsics?
|
Mar 01, 2022 |
|
The private health insurances as the entrance into German market access – is this true, Dr. Bastian Biermann?
|
Feb 15, 2022 |
|
How can a company derive the optimal price for their medical product, Dr. Renato Dellamano?
|
Feb 01, 2022 |
|
How do innovations reach patients in German hospitals, Dr. Sebastian Casu?
|
Jan 15, 2022 |
|
How does hospital funding work in Germany, Willi Wöllner?
|
Jan 01, 2022 |
|
Prof. Dr. Jürgen Wasem - What happens, when negotiations fail?
|
Dec 15, 2021 |
|
Dr. Michael Zuercher - Commercial attractiveness of the Swiss health care market – success starts with market access.
|
Dec 01, 2021 |
|
Prof. Peter Zweifel & Door Vonk - Digital innovation - from theory into practice!
|
Nov 15, 2021 |
|
Bibiane Schulte-Bosse - How to fight well in AMNOG negotiations.
|
Nov 01, 2021 |
|
Prof. Dr. David Matusiewicz & Dr. Anne Sophie Geier - 1 year DIGAs. Is the "fast track process" for digital health applications successful?
|
Oct 15, 2021 |
|
Remo Christen – Early paid access in Switzerland – Switzerland, wonderland??
|
Oct 01, 2021 |
|
Prof. Dr. Wagschal - What can we expect from the upcoming elections in Germany?
|
Sep 15, 2021 |
|
Dr. Mathias Flume - AMNOG will change in 2022, but how?
|
Sep 02, 2021 |